Abstract：Objective: To investigate the efficacy, safety and stability outcomes of central-hole posterior chamber collamer phakic intraocular lens implantation in the correction of low-to-moderate myopia. Methods: This retrospective cohort study included 707 eyes of 490 consecutive patientes submitted to posterior chamber collamer phakic intraocular lens implantation that completed a 6-month postoperative follow-up. Efficacy, predictability, stability and safety outcomes were demonstrated preoperatively and at 1, 3 and 6 months postoperatively. Results: At 6 months postoperative, uncorrected and best corrected visual acuities were -0.076±0.079 logMAR and -0.079±0.080 logMAR, with an efficacy index of 1.26±0.21 and safety index of 1.13±0.18 respectively; 94.9% eyes were within ±0.50 D of targeted refraction. The spherical equivalent was -0.063±0.135 D at 1 month and -0.071±0.126 D at 6 months postoperatively. The endothelial cells was 3 078±258 /mm2 preopearatively and 2 953±206 /mm2 at 6 months postoperatively; the mean rate of endothelial cell loss was (1.05±0.39)%. The mean vault were 498±143 μm and 474±177 μm at 1 month and 6 months after operation respectively. The rate of the ICL exchange was 1.4%. No vision-threatening complications were reported. Conclusion: The posterior chamber collamer phakic intraocular lens implantation demonstrates high refractive efficacy and an excellent safety profile for the correction of lowto-moderate myopia.
浙公网安备 33030202001892号